Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lifitegrast. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 known ✓ | P05107 | 20/20 | 1.00 |
| ▸ | ITGAL known ✓ | P20701 | 20/20 | 1.00 |
| ▸ | ICAM1 | P05362 | 20/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lifitegrast SCHEMBL29355715 | 1.00 | ITGB2 (1.00) | ITGB2ICAM1ITGALCYP2C9 | |
| Lifitegrast SCHEMBL31010393 | 1.00 | ITGB2 (1.00) | ITGB2ICAM1ITGALCYP2C9 | |
| Lifitegrast SCHEMBL29386183 | 1.00 | ITGB2 (1.00) | ITGB2ICAM1ITGALCYP2C9 | |
| Lifitegrast SCHEMBL22556043 | 1.00 | ITGB2 (1.00) | ITGB2ICAM1ITGALCYP2C9 | |
| Lifitegrast SCHEMBL13167919 | 1.00 | ITGB2 (1.00) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL28561637 | 0.97 | ITGB2 (0.95) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL15445331 | 0.96 | ITGB2 (0.92) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL22929996 | 0.95 | ITGB2 (0.90) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL19134124 | 0.95 | ITGB2 (0.90) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL4756175 | 0.95 | ITGB2 (0.90) | ITGB2ICAM1ITGALCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 250 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240197713-A1 | LFA-1 ANTAGONISTS FOR TREATING INFLAMMATORY BOWEL DIESEASE | VIVAVISION BIOTECH INC (CN) | 2024-06-20 | — | — | US | claimed |
| US-20240166691-A1 | PRODRUGS AND COMPOSITIONS FOR OPHTHALMOLOGY APPLICATIONS | ALCON INC. (CH) | 2024-05-23 | — | — | US | claimed |
| WO-2024100552-A1 | PRODRUGS AND COMPOSITIONS FOR OPHTHALMOLOGY APPLICATIONS | ALCON INC. (CH) | 2024-05-16 | — | — | WO | claimed |
| CN-110996904-A | Ophthalmic compositions and methods of use | 奥古根有限公司 | 2020-04-10 | — | — | CN | claimed |
| WO-2019043724-A1 | PROCESSES FOR THE PREPARATION OF (S)-2-(2-(BENZOFURAN-6-CARBONYL)-5,7-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE-6-CARBOXAMIDO)-3-(3-(METHYLSULFONYL)PHENYL) PROPANOIC ACID AND POLYMORPHS THEREOF | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2019-03-07 | — | — | WO | claimed |
| US-20180333414-A1 | OPHTHALMIC COMPOSITIONS AND METHODS OF USE | Ocugen, Inc. (US) | 2018-11-22 | — | — | US | claimed |
| US-20260027050-A1 | ACOLTREMON COMBINATIONS AND USES THEREOF | ALCON INC (CH) | 2026-01-29 | — | — | US | disclosed |
| US-20240197713-A1 | LFA-1 ANTAGONISTS FOR TREATING INFLAMMATORY BOWEL DIESEASE | VIVAVISION BIOTECH INC (CN) | 2024-06-20 | — | — | US | disclosed |
| US-20240166691-A1 | PRODRUGS AND COMPOSITIONS FOR OPHTHALMOLOGY APPLICATIONS | ALCON INC. (CH) | 2024-05-23 | — | — | US | disclosed |
| WO-2024042550-A1 | OPHTHALMIC COMBINATION COMPOSITION | SENTISS PHARMA PRIVATE LIMITED (IN) | 2024-02-29 | — | — | WO | disclosed |
| EP-3807268-B1 | PROCESS FOR THE PREPARATION OF LIFITEGRAST | OLON SPA (IT) | 2024-01-24 | — | — | EP | disclosed |
| EP-3807268-B1 | PROCESS FOR THE PREPARATION OF LIFITEGRAST | OLON SPA (IT) | 2024-01-24 | — | — | EP | disclosed |
| US-20230399317-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2023-12-14 | — | — | US | disclosed |
| US-20090257957-A1 | Aerosolized LFA-1 antagonists for use in localized treatment of immune related disorders | NOVARTIS AG (CH) | 2009-10-15 | — | — | US | disclosed |
| US-20090257957-A1 | Aerosolized LFA-1 antagonists for use in localized treatment of immune related disorders | NOVARTIS AG (CH) | 2009-10-15 | — | — | US | disclosed |
| US-20090258069-A1 | Delivery of LFA-1 antagonists to the gastrointestinal system | NOVARTIS AG (CH) | 2009-10-15 | — | — | US | disclosed |
| US-20090258069-A1 | Delivery of LFA-1 antagonists to the gastrointestinal system | NOVARTIS AG (CH) | 2009-10-15 | — | — | US | disclosed |
| US-20090155176-A1 | Compositions and methods for treatment of diabetic retinopathy | SARCODE CORPORATION (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090155176-A1 | Compositions and methods for treatment of diabetic retinopathy | SARCODE CORPORATION (US) | 2009-06-18 | — | — | US | disclosed |
| WO-2009054914-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY | SARCODE CORPORATION (US) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240197713-A1 | LFA-1 ANTAGONISTS FOR TREATING INFLAMMATORY BOWEL DIESEASE | CD69, VCAM1, CD58 | ITGB2 38/4885ITGAL 17/4885ICAM1 4/4885 |
| US-20230399317-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | MPO, MUC1, CRYAB | ITGB2 1162/4885ITGAL 1166/4885ICAM1 271/4885 |
| US-20090155176-A1 | Compositions and methods for treatment of diabetic retinopathy | VCAM1, ITGB1, ICAM1 | ITGB2 11/4885ITGAL 5/4885ICAM1 3/4885 |
| US-20260027050-A1 | ACOLTREMON COMBINATIONS AND USES THEREOF | TRPC7, TRPC5, TSLP | ITGB2 2598/4885ITGAL 734/4885ICAM1 2044/4885 |
| US-20240166691-A1 | PRODRUGS AND COMPOSITIONS FOR OPHTHALMOLOGY APPLICATIONS | PDE6C, PDE6D, PDE6B | ITGB2 2329/4885ITGAL 1535/4885ICAM1 4561/4885 |
| US-20090258069-A1 | Delivery of LFA-1 antagonists to the gastrointestinal system | VCAM1, ITGAL, HAVCR2 | ITGB2 12/4885ITGAL 2/4885ICAM1 4/4885 |
| US-20090257957-A1 | Aerosolized LFA-1 antagonists for use in localized treatment of immune related disorders | ICAM1, ITGAL, ITGA1 | ITGB2 9/4885ITGAL 2/4885ICAM1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.